Baird upgraded Tandem Diabetes (TNDM) to Outperform from Neutral with a price target of $30, up from $18. The firm adjusted ratings and medical technology as part of its 2026 outlook. Baird cites solid end markets, the company’s pharmacy revenue and margin tailwinds, and the Mobi-T mid-year launch for the upgrade of Tandem.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Citi ups Tandem target, adds ‘downside 90-day catalyst watch’
- Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley
- Tandem Diabetes Care Appoints Sandra Beaver to Board
- Tandem Diabetes price target raised to $17 from $13 at Morgan Stanley
- Tandem Diabetes receives FDA clearance for use with Android smartphones